Business context and reporting period
Important entity discrepancy: The supplied filing is Priveterra Acquisition Corp.’s Form 10-Q for the quarter ended June 30, 2021, not an AEON Biopharma filing. Priveterra was a blank-check company formed to pursue a business combination; it had not begun operations or generated operating revenue.
Financial results and position
- Revenue: None. The company reported no operating revenue.
- Net income/(loss): Six months ended June 30, 2021: net income of $2.294 million, primarily from a $3.511 million unrealized warrant fair-value gain. Three months ended June 30, 2021: net loss of $4.025 million, including a $3.655 million warrant fair-value loss. Operating costs were $599,306 for six months and $398,443 for the quarter. Results were therefore substantially affected by noncash warrant remeasurement.
- Cash flow and liquidity: Operating cash use was $1.007 million for the six months. At June 30, cash outside the trust was $988,855 and working capital was approximately $1.2 million. The trust account held $276.037 million in U.S. Treasury bills. Management said available working capital and borrowing capacity should cover needs through a business combination or one year from filing.
- Assets, liabilities, and equity: Total assets were $277.615 million; total liabilities were $24.452 million; stockholders’ equity was $5.000 million. The balance sheet included a $14.586 million warrant liability, $9.660 million deferred underwriting discount payable only if a business combination closes, and $248.163 million of Class A shares classified as temporary equity due to redemption rights. No working-capital loan balance remained at quarter-end.
- Margins and debt: Not meaningful for a pre-combination SPAC without revenue. No outstanding working-capital borrowings were reported at June 30.
Changes versus prior period
The company completed its IPO on February 11, 2021, raising $276 million from 27.6 million units and placing $276 million in trust; it also raised approximately $7.82 million through private-placement warrants. The filing provides no comparable prior-year operating results because the company was newly formed and had no operations. Balance-sheet comparisons with December 31, 2020 principally reflect the IPO and trust funding.
Outlook, risks, and unusual items
- The company had until February 11, 2023—24 months after the IPO—to complete a business combination; otherwise, it generally must redeem public shares and liquidate.
- Management reported no material change to previously disclosed risk factors. It said the specific effect of COVID-19 on the company’s finances or target search could not be determined.
- The Sponsor’s trust-account indemnity may not be collectible: the company had not required a reserve and had not verified the Sponsor’s ability to pay.
- Warrants are recorded as liabilities and remeasured at fair value, creating potentially material earnings volatility. Private-warrant valuation uses significant unobservable inputs.
- Management disclosed a correction to previously issued equity information, including omitted parentheses for certain reductions and a March 31 additional-paid-in-capital balance that had not been updated.
- Disclosure controls were deemed ineffective at quarter-end because of a material weakness related to complex SPAC warrant accounting. Management described remediation efforts but gave no assurance they would be effective.
- The filing reports $9.660 million of deferred underwriting fees due only upon completion of a business combination, plus monthly administrative-service fees of up to $25,000 until a combination or liquidation.
Key facts for investors to verify
- Confirm the filing entity: this 10-Q is for Priveterra Acquisition Corp., not AEON Biopharma, Inc.
- Review the warrant-liability valuation and its effect on reported earnings.
- Assess cash available outside the trust, expected deal-search expenses, and the Sponsor’s optional funding capacity.
- Track the February 2023 business-combination deadline, redemption terms, and deferred underwriting fee.
- Check remediation of the disclosed material weakness and the accounting correction in subsequent filings.